SecBot SecBot
SECBOTREPLAY Home › Report › NKTX

NKTX · Nkarta announced FDA agreement on protocol amendments for its Ntrust-1…

Nkarta, Inc. · PRESS-RELEASE filed Apr 15, 2026 at 16:01 ET

At the news

BULLISHIMPACT 7/10

PRESS-RELEASE filed Apr 15, 2026 at 16:01 ET

Nkarta announced FDA agreement on protocol amendments for its Ntrust-1 and Ntrust-2 trials, enabling outpatient dosing, redosing flexibility, and expansion into rheumatoid arthritis. These changes reduce patient burden and broaden trial accessibility, supporting clinical development of its CAR-NK therapy NKX019 for autoimmune diseases.

  • FDA agreed to protocol amendments allowing outpatient administration of NKX019 with monitoring reduced from 24 hours to 2 hours
  • Option to re-dose patients added in both Ntrust-1 and Ntrust-2 trials
  • Rheumatoid arthritis cohort to be added to Ntrust-2 trial
  • No geographic monitoring requirements remain, reducing patient burden

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access